FBXO7 Inhibitor Compounds for Neurodegenerative Disease Treatment - University of Pittsburgh
Summary
The University of Pittsburgh has filed patent application US20260109687A1 covering methods for treating neurodegenerative diseases and inflammatory disorders using FBXO7 inhibitor compounds. The application, filed on July 28, 2025, names Rama K. Mallampalli, Beibei Chen, Charleen T. Chu, and Yuan Liu as inventors. The claimed compounds are chemical inhibitors of the E3 ligase subunit FBXO7 that confer neuroprotection and anti-inflammatory activity by stabilizing mitochondria.
About this source
USPTO classification C07D covers heterocyclic organic compounds: the chemical core of most small-molecule drugs, including kinase inhibitors, GLP-1 receptor agonists, antibiotics, antivirals, and CNS therapies. Every newly published application in C07D lands in this feed, around 160 a month. Applications publish 18 months after filing, so this feed reveals what medicinal chemistry groups at Pfizer, Novartis, Roche, Shionogi, and others were synthesizing in the prior year and a half. Watch this if you run a medicinal chemistry program, file patent clearance for new drug candidates, scout competitor pipelines before clinical readouts, or track heterocyclic innovation across therapeutic areas.
What changed
The University of Pittsburgh has published a patent application (US20260109687A1) for a method of treating neurodegenerative diseases or inflammatory disorders using compounds that inhibit the E3 ligase subunit FBXO7. The application claims compounds of formula II with substituents R3-R7 (independently H, halogen, alkyl, amino, alkoxy, or hydroxy) and R8 (optionally-substituted heterocycloalkyl). The mechanism involves stabilizing mitochondria to confer neuroprotection and anti-inflammatory activity.
For parties interested in neurological therapeutics, this patent application signals potential future exclusivity claims in the FBXO7 inhibitor space for neurodegenerative disease treatment. Researchers and pharmaceutical developers working on mitochondrial stabilization therapies for Parkinson's disease, ALS, or related conditions should review the claimed compound scope for freedom-to-operate considerations.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
CHEMICAL INHIBITION OF THE E3 LIGASE SUBUNIT FBXO7 CONFERS NEUROPROTECTION AND ANTI-INFLAMMATORY ACTIVITY BY STABILIZING MITOCHONDRIA
Application US20260109687A1 Kind: A1 Apr 23, 2026
Assignee
University of Pittsburgh - Of the Commonwealth System of Higher Education
Inventors
Rama K. Mallampalli, Beibei Chen, Charleen T. Chu, Yuan Liu
Abstract
A method for treating a neurodegenerative disease or an inflammatory disorder in a subject, comprising administering to the subject in need thereof, a compound, or a pharmaceutically acceptable salt thereof, of formula II: wherein each of R3-R7 is independently H, halogen, optionally-substituted alkyl, amino, alkoxy or hydroxy;R8 is an optionally-substituted heterocycloalkyl; anda is 0 to 3.
CPC Classifications
C07D 405/12 A61K 31/517 A61P 25/16 A61P 25/28
Filing Date
2025-07-28
Application No.
19282869
Named provisions
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Applications - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.